Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report released on Thursday. The firm set a “sell” rating on the stock.

MBRX has been the subject of several other reports. Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Moleculin Biotech in a research note on Monday, March 3rd.

Moleculin Biotech Price Performance

Shares of NASDAQ MBRX opened at $1.26 on Thursday. Moleculin Biotech has a twelve month low of $0.40 and a twelve month high of $8.85. The business’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $2.09.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.